{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:46:39Z","timestamp":1790480799765,"version":"4.1.0"},"reference-count":246,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Genomic instability stands out as a pivotal hallmark of cancer, and PARP inhibitors (PARPi) emerging as a groundbreaking class of targeted therapy drugs meticulously crafted to inhibit the repair of DNA single-strand breaks(SSB) in tumor cells. Currently, PARPi have been approved for the treatment of ovarian cancer, pancreatic cancer, breast cancer, and prostate cancer characterized by homologous recombination(HR) repair deficiencies due to mutations in BRCA1\/2 or other DNA repair associated genes and acquiring the designation of breakthrough therapy. Nonetheless, PARPi exhibit limited efficacy in the majority of HR-proficient\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    wild-type cancers. At present, the synergistic approach of combining PARPi with agents that induce HR defects, or with chemotherapy and radiotherapy to induce substantial DNA damage, significantly enhances the efficacy of PARPi in\n                    <jats:italic>BRCA<\/jats:italic>\n                    wild-type or HR-proficient patients, supporting extension the use of PARPi in HR proficient patients. Therefore, we have summarized the effects and mechanisms of the combined use of drugs with PARPi, including the combination of PARPi with HR defect-inducing drugs such as ATRi, CHKi, HR indirectly inducing drugs like VEGFRi, CDKi, immune checkpoint inhibitors and drugs instigating DNA damage such as chemotherapy or radiotherapy. In addition, this review discusses several ongoing clinical trials aimed at analyzing the clinical application potential of these combined treatment strategies.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2024.1441222","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:57:24Z","timestamp":1722560244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Yijun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2009.08.009","article-title":"Poly(Adp-ribose) polymerase 1 regulates activity of DNA polymerase beta in long patch base excision repair","volume":"685","author":"Sukhanova","year":"2010","journal-title":"Mutat Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(Adp-ribose) polymerase inhibition: Past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106425","article-title":"Targeting cancer stem cells in the tumor microenvironment: An emerging role of parp inhibitors","volume":"184","author":"Paul","year":"2022","journal-title":"Pharmacol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1042\/EBC20190093","article-title":"Mechanism and significance of chromosome damage repair by homologous recombination","volume":"64","author":"Kawale","year":"2020","journal-title":"Essays Biochem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-biochem-060614-034352","article-title":"Mechanics and single-molecule interrogation of DNA recombination","volume":"85","author":"Bell","year":"2016","journal-title":"Annu Rev Biochem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443","article-title":"Specific killing of brca2-deficient tumours with inhibitors of poly(Adp-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-0968","article-title":"Parp inhibitors: Extending benefit beyond brca-mutant cancers","volume":"25","author":"Pili\u00e9","year":"2019","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of parp1 and parp2 by clinical parp inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: Parp inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Trans Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344","article-title":"Parp inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Sci (New York NY)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.034","article-title":"Simultaneous targeting of parp1 and rad52 triggers dual synthetic lethality in brca-deficient tumor cells","volume":"23","author":"Sullivan-Reed","year":"2018","journal-title":"Cell Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1335196","article-title":"How brca and homologous recombination deficiency change therapeutic strategies in ovarian cancer: A review of literature","volume":"14","author":"Arcieri","year":"2024","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001556","article-title":"Ovarian cancer predisposition beyond brca1 and brca2 genes","volume":"30","author":"Pietragalla","year":"2020","journal-title":"Int J gynecological cancer: Off J Int Gynecological Cancer Soc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01352","article-title":"Multi-therapies based on parp inhibition: Potential therapeutic approaches for cancer treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J medicinal Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: Poly(Adp) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1091496","article-title":"Direct activation of the atm protein kinase by the mre11\/rad50\/nbs1 complex","volume":"304","author":"Lee","year":"2004","journal-title":"Sci (New York NY)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1108297","article-title":"Atm activation by DNA double-strand breaks through the mre11-rad50-nbs1 complex","volume":"308","author":"Lee","year":"2005","journal-title":"Sci (New York NY)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105440118","article-title":"DNA damage-induced phosphorylation of ctip at a conserved atm\/atr site T855 promotes lymphomagenesis in mice","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1038\/s41467-020-19202-0","article-title":"Usp52 regulates DNA end resection and chemosensitivity through removing inhibitory ubiquitination from ctip","volume":"11","author":"Gao","year":"2020","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1038\/s41467-023-40672-5","article-title":"A rad51-adp double filament structure unveils the mechanism of filament dynamics in homologous recombination","volume":"14","author":"Luo","year":"2023","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(Adp-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34162","article-title":"Brd4 inhibitor azd5153 suppresses the proliferation of colorectal cancer cells and sensitizes the anticancer effect of parp inhibitor","volume":"15","author":"Zhang","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccell.2019.12.015","article-title":"Ezh2 inhibition sensitizes carm1-high, homologous recombination proficient ovarian cancers to parp inhibition","volume":"37","author":"Karakashev","year":"2020","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Saha), enhances anti-tumor effects of the poly (Adp-ribose) polymerase (Parp) inhibitor olaparib in triple-negative breast cancer cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer research: BCR"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2450","article-title":"Atr: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by atr inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap9346","article-title":"An intrinsic S\/G(2) checkpoint enforced by atr","volume":"361","author":"Saldivar","year":"2018","journal-title":"Sci (New York NY)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr697","article-title":"Safeguarding genome integrity: The checkpoint kinases atr, chk1 and wee1 restrain cdk activity during normal DNA replication","volume":"40","author":"S\u00f8rensen","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase atr: Ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112792","article-title":"Atr protects ongoing and newly assembled DNA replication forks through distinct mechanisms","volume":"42","author":"Leung","year":"2023","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1101\/gad.851000","article-title":"Functional interactions between brca1 and the checkpoint kinase atr during genotoxic stress","volume":"14","author":"Tibbetts","year":"2000","journal-title":"Genes Dev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.6.4532","article-title":"Regulation of brca1 expression by the rb-E2f pathway","volume":"275","author":"Wang","year":"2000","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2013.06.063","article-title":"Chk1 inhibits E2f6 repressor function in response to replication stress to maintain cell-cycle transcription","volume":"23","author":"Bertoli","year":"2013","journal-title":"Curr biology: CB"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky625","article-title":"Atr-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells","volume":"46","author":"Kim","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of homologous recombination and the checkpoint by atr","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1038\/s41598-022-09308-4","article-title":"A clinically relevant heterozygous atr mutation sensitizes colorectal cancer cells to replication stress","volume":"12","author":"Egger","year":"2022","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/plcell\/koad126","article-title":"The atr-wee1 kinase module promotes suppressor of gamma response 1 translation to activate replication stress responses","volume":"35","author":"Chen","year":"2023","journal-title":"Plant Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2015.00070","article-title":"Targeting lung cancer through inhibition of checkpoint kinases","volume":"6","author":"Randi","year":"2015","journal-title":"Front Genet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249715","article-title":"Parp inhibition increases the reliance on atr\/chk1 checkpoint signaling leading to synthetic lethality-an alternative treatment strategy for epithelial ovarian cancer cells independent from hr effectiveness","volume":"21","author":"Gralewska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"Atr\/chk1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiotherapy oncology: J Eur Soc Ther Radiol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125482","article-title":"A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined atr inhibition and cisplatin treatments","volume":"10","author":"Mohni","year":"2015","journal-title":"PLoS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111081","article-title":"Guiding atr and parp inhibitor combinationswith chemogenomic screens","volume":"40","author":"Zimmermann","year":"2022","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.6","article-title":"Gammah2ax: A sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.526","article-title":"Therapeutic targeting of the DNA damage response using an atr inhibitor in biliary tract cancer","volume":"51","author":"Nam","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"Atr inhibitor azd6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the parp inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining parp with atr inhibition overcomes parp inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"B50","article-title":"Chk1 inhibition potentiates the therapeutic efficacy of parp inhibitor bmn673 in gastric cancer","volume":"7","author":"Yin","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2007.23","article-title":"Identification of novel substrates for human checkpoint kinase chk1 and chk2 through genome-wide screening using a consensus chk phosphorylation motif","volume":"39","author":"Kim","year":"2007","journal-title":"Exp Mol Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2020.1711577","article-title":"Phosphatase popx2 interferes with cell cycle by interacting with chk1","volume":"19","author":"Kim","year":"2020","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1101\/gad.608210","article-title":"Cohesin organizes chromatin loops at DNA replication factories","volume":"24","author":"Guillou","year":"2010","journal-title":"Genes Dev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13058","article-title":"Ubqln4 is an atm substrate that stabilizes the anti-apoptotic proteins bcl2a1 and bcl2l10 in mesothelioma","volume":"15","author":"Liu","year":"2021","journal-title":"Mol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111744","article-title":"Coexisting germline chek2 and somatic braf(V600e) mutations in papillary thyroid cancer and their association with clinicopathological features and disease course","volume":"11","author":"G\u0105sior-Perczak","year":"2019","journal-title":"Cancers"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.7.8040","article-title":"Claspin and chk1 regulate replication fork stability by different mechanisms","volume":"8","author":"Scorah","year":"2009","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005031107","article-title":"Chk1 promotes replication fork progression by controlling replication initiation","volume":"107","author":"Petermann","year":"2010","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.17","article-title":"The checkpoint kinases chk1 and chk2 regulate the functional associations between hbrca2 and rad51 in response to DNA damage","volume":"27","author":"Bahassi","year":"2008","journal-title":"Oncogene"},{"key":"B59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ncb1212","article-title":"The cell-cycle checkpoint kinase chk1 is required for mammalian homologous recombination repair","volume":"7","author":"S\u00f8rensen","year":"2005","journal-title":"Nat Cell Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.312537","article-title":"Inhibition of chk 1 (Checkpoint kinase 1) elicits therapeutic effects in pulmonary arterial hypertension","volume":"39","author":"Bourgeois","year":"2019","journal-title":"Arteriosclerosis thrombosis Vasc Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.09.016","article-title":"Reality chek: understanding the biology and clinical potential of chk1","volume":"497","author":"Neizer-Ashun","year":"2021","journal-title":"Cancer Lett"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the atr\/chk1 axis with parp inhibition results in tumor regression in brca-mutant ovarian cancer models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.24424","article-title":"Parp and chk inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells","volume":"14","author":"Booth","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.1013","article-title":"Enhanced efficacy of combined therapy with checkpoint kinase 1 inhibitor and rucaparib via regulation of rad51 expression in brca wild-type epithelial ovarian cancer cells","volume":"53","author":"Cho","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209874","article-title":"The roles of brca1 and brca2 and associated proteins in the maintenance of genomic stability","volume":"25","author":"Gudmundsdottir","year":"2006","journal-title":"Oncogene"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2523","article-title":"Gammah2ax and cancer","volume":"8","author":"Bonner","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(Adp-ribose) polymerase in tumors from brca mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"New Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-08-3114","article-title":"Gammah2ax expression in tumors exposed to cisplatin and fractionated irradiation","volume":"15","author":"Ba\u00f1uelos","year":"2009","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2ax phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"B70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-genet-021920-092410","article-title":"Rad51 gene family structure and function","volume":"54","author":"Bonilla","year":"2020","journal-title":"Annu Rev Genet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac009","article-title":"Topors-mediated rad51 sumoylation facilitates homologous recombination repair","volume":"50","author":"Hariharasudhan","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016410","article-title":"An overview of the molecular mechanisms of recombinational DNA repair","volume":"7","author":"Kowalczykowski","year":"2015","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.935593","article-title":"The emerging roles of rad51 in cancer and its potential as a therapeutic target","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy099","article-title":"Rad51 foci as a functional biomarker of homologous recombination repair and parp inhibitor resistance in germline brca-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1348","article-title":"Rad51 mediates resistance of cancer stem cells to parp inhibition in triple-negative breast cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.chembiol.2021.02.006","article-title":"A small-molecule inhibitor of the brca2-rad51 interaction modulates rad51 assembly and potentiates DNA damage-induced cell death","volume":"28","author":"Scott","year":"2021","journal-title":"Cell Chem Biol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e38254","DOI":"10.1371\/journal.pone.0038254","article-title":"High expression of wee1 is associated with poor disease-free survival in Malignant melanoma: potential for targeted therapy","volume":"7","author":"Magnussen","year":"2012","journal-title":"PLoS One"},{"key":"B78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-018-0641-1","article-title":"Targeting wee1 to enhance conventional therapies for acute lymphoblastic leukemia","volume":"11","author":"Ghelli Luserna Di Ror\u00e0","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting wee1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828684","article-title":"Targeting the DNA damage response for cancer therapy by inhibiting the kinase wee1","volume":"12","author":"Bukhari","year":"2022","journal-title":"Front Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v6i15","article-title":"Wee1 is required to sustain atr\/chk1 signaling upon replicative stress","volume":"6","author":"Saini","year":"2015","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201101047","article-title":"Wee1 controls genomic stability during replication by regulating the mus81-eme1 endonuclease","volume":"194","author":"Dom\u00ednguez-Kelly","year":"2011","journal-title":"J Cell Biol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710291105","article-title":"Cleavage mechanism of human mus81-eme1 acting on holliday-junction structures","volume":"105","author":"Taylor","year":"2008","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.9.7.11115","article-title":"Mk-1775, a small molecule wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"Hirai","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.296","article-title":"Forced activation of cdk1 via wee1 inhibition impairs homologous recombination","volume":"32","author":"Krajewska","year":"2013","journal-title":"Oncogene"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2015.09.006","article-title":"Sensitization of pancreatic cancers to gemcitabine chemoradiation by wee1 kinase inhibition depends on homologous recombination repair","volume":"17","author":"Kausar","year":"2015","journal-title":"Neoplasia (New York NY)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.473","article-title":"Inhibition of wee1 potentiates sensitivity to parp inhibitor in biliary tract cancer","volume":"54","author":"Seo","year":"2022","journal-title":"Cancer Res Treat"},{"key":"B88","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential therapy with parp and wee1 inhibitors minimizes toxicity while maintaining efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071656","article-title":"Targeting replicative stress and DNA repair by combining parp and wee1 kinase inhibitors is synergistic in triple negative breast cancers with cyclin E or brca1 alteration","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00568-5","article-title":"Combined parp and wee1 inhibition triggers anti-tumor immune response in brca1\/2 wildtype triple-negative breast cancer","volume":"9","author":"Teo","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.12.006","article-title":"Cdk inhibitors from past to present: A new wave of cancer therapy","volume":"88","author":"Mughal","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2f dysfunction in cancer","volume":"19","author":"Kent","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1159\/000058531","article-title":"Disruption of the P16\/cyclin D1\/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas","volume":"60","author":"Azechi","year":"2001","journal-title":"Oncology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24329","article-title":"Rb1 in cancer: different mechanisms of rb1 inactivation and alterations of prb pathway in tumorigenesis","volume":"228","author":"Di Fiore","year":"2013","journal-title":"J Cell Physiol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2021.01.010","article-title":"New insights into cdk regulators: novel opportunities for cancer therapy","volume":"31","author":"Bury","year":"2021","journal-title":"Trends Cell Biol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020572","article-title":"Prognostic potential of cyclin D1 expression in colorectal cancer","volume":"12","author":"Jun","year":"2023","journal-title":"J Clin Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0959","article-title":"Minireview: cyclin D1: Normal and abnormal functions","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.breast.2018.10.001","article-title":"Targeting cdk4\/6 pathways and beyond in breast cancer","volume":"43","author":"Ribnikar","year":"2019","journal-title":"Breast (Edinburgh Scotland)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.354","article-title":"Cyclin D1 promotes brca2-rad51 interaction by restricting cyclin a\/B-dependent brca2 phosphorylation","volume":"35","author":"Chalermrujinanant","year":"2016","journal-title":"Oncogene"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073555","article-title":"Cyclin-dependent kinase synthetic lethality partners in DNA damage response","volume":"23","author":"Kciuk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.21.11866","article-title":"Brca1-associated growth arrest is rb-dependent","volume":"96","author":"Aprelikova","year":"1999","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2377","article-title":"Compromised cdk1 activity sensitizes brca-proficient cancers to parp inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"Cdk12 inhibition reverses de novo and acquired parp inhibitor resistance in brca wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106683","article-title":"Discovery of dual parp and cdk6 inhibitors for triple-negative breast cancer with wild-type brca","volume":"139","author":"Wang","year":"2023","journal-title":"Bioorganic Chem"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2022.06.021","article-title":"Vegfr endocytosis: implications for angiogenesis","volume":"194","author":"Saikia","year":"2023","journal-title":"Prog Mol Biol Trans Sci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of vegf\/vegfr in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102224","article-title":"Recent advancements of antiangiogenic combination therapies in ovarian cancer","volume":"98","author":"An","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109902","article-title":"Parp inhibitor veliparib (Abt-888) enhances the anti-angiogenic potentiality of curcumin through deregulation of nectin-4 in oral cancer: role of nitric oxide (No)","volume":"80","author":"Chatterjee","year":"2021","journal-title":"Cell signalling"},{"key":"B109","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.neo.2014.04.003","article-title":"Vegfr3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of brca1 and brca2","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia (New York NY)"},{"key":"B110","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12885-022-09271-3","article-title":"Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: A retrospective analysis","volume":"22","author":"Suminokura","year":"2022","journal-title":"BMC Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/GCO.0000000000000428","article-title":"Novel poly-adp-ribose polymerase inhibitor combination strategies in ovarian cancer","volume":"30","author":"McCann","year":"2018","journal-title":"Curr Opin obstetrics gynecology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30005-X","article-title":"Olaparib plus bevacizumab improves progression-free survival in ovarian cancer","volume":"21","author":"Gourd","year":"2020","journal-title":"Lancet Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207399","article-title":"Combination of triapine, olaparib, and cediranib suppresses progression of brca-wild type and parp inhibitor-resistant epithelial ovarian cancer","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS One"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30515-7","article-title":"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (Nsgo-avanova2\/engot-ov24): A randomised, phase 2, superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"New Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase ii study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (Nrg-gy004): A randomized, open-label, phase iii trial","volume":"40","author":"Liu","year":"2022","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00640","article-title":"Discovery, synthesis, and evaluation of novel dual inhibitors of a vascular endothelial growth factor receptor and poly(Adp-ribose) polymerase for brca wild-type breast cancer therapy","volume":"66","author":"Li","year":"2023","journal-title":"J medicinal Chem"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32041","article-title":"Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue","volume":"125","author":"Schnekenburger","year":"2019","journal-title":"Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112280","article-title":"Loss of ezh2 function remodels the DNA replication initiation landscape","volume":"42","author":"Prorok","year":"2023","journal-title":"Cell Rep"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102600","article-title":"Review: targeting ezh2 in neuroblastoma","volume":"119","author":"Gao","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00047","article-title":"Targeting enhancer of zeste homolog 2 for the treatment of hematological Malignancies and solid tumors: candidate structure-activity relationships insights and evolution prospects","volume":"65","author":"Xia","year":"2022","journal-title":"J medicinal Chem"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116054","article-title":"Dual target parp1\/ezh2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy","volume":"265","author":"Li","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4036","article-title":"Targeting ezh2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4092","article-title":"An oncogenic ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation","volume":"22","author":"Souroullas","year":"2016","journal-title":"Nat Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41388-023-02618-5","article-title":"Dissecting and targeting noncanonical functions of ezh2 in multiple myeloma via an ezh2 degrader","volume":"42","author":"Yu","year":"2023","journal-title":"Oncogene"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.965244","article-title":"Combined inhibition of parp and ezh2 for cancer treatment: current status, opportunities, and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.celrep.2019.12.056","article-title":"Inhibition of ezh2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast cancer","volume":"30","author":"Yomtoubian","year":"2020","journal-title":"Cell Rep"},{"key":"B129","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","article-title":"Context-specific regulation of nf-\u039ab target gene expression by ezh2 in breast cancers","volume":"43","author":"Lee","year":"2011","journal-title":"Mol Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1308953111","article-title":"Ezh2 expands breast stem cells through activation of notch1 signaling","volume":"111","author":"Gonzalez","year":"2014","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B131","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-023-01786-y","article-title":"Ezh2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15636","article-title":"Parp1 and prc2 double deficiency promotes brca-proficient breast cancer growth by modification of the tumor microenvironment","volume":"288","author":"Yang","year":"2021","journal-title":"FEBS J"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nature11606","article-title":"Ezh2 inhibition as a therapeutic strategy for lymphoma with ezh2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00567","article-title":"Discovery of first-in-class dual parp and ezh2 inhibitors for triple-negative breast cancer with wild-type brca","volume":"64","author":"Wang","year":"2021","journal-title":"J medicinal Chem"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.11.005","article-title":"Anticancer properties of chimeric hdac and kinase inhibitors","volume":"83","author":"Biersack","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2005.37.2.122","article-title":"A histone deacetylase inhibitor, trichostatin a, enhances radiosensitivity by abrogating G2\/M arrest in human carcinoma cells","volume":"37","author":"Kim","year":"2005","journal-title":"Cancer Res Treat"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-018-0097-1","article-title":"Acetylation blocks DNA damage-induced chromatin adp-ribosylation","volume":"14","author":"Liszczak","year":"2018","journal-title":"Nat Chem Biol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"Parp inhibitor veliparib and hdac inhibitor saha synergistically co-target the uhrf1\/brca1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of parp inhibitors: anticancer therapy and beyond","volume":"34","author":"Curtin","year":"2013","journal-title":"Mol aspects Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.maturitas.2015.01.015","article-title":"Parp inhibitors: A new era of targeted therapy","volume":"81","author":"Tangutoori","year":"2015","journal-title":"Maturitas"},{"key":"B142","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/med.21320","article-title":"Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy","volume":"35","author":"Zhang","year":"2015","journal-title":"Medicinal Res Rev"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v5i14","article-title":"Histone deacetylase inhibitor treatment induces 'Brcaness' and synergistic lethality with parp inhibitor and cisplatin against human triple negative breast cancer cells","volume":"5","author":"Ha","year":"2014","journal-title":"Oncotarget"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.01.045","article-title":"Co-targeting poly(Adp-ribose) polymerase (Parp) and histone deacetylase (Hdac) in triple-negative breast cancer: higher synergism in brca mutated cells","volume":"99","author":"Marijon","year":"2018","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v13","article-title":"Hdac inhibitors suppress protein poly(Adp-ribosyl)Ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with parp inhibitors and chemotherapeutic drugs","volume":"13","author":"Valdez","year":"2022","journal-title":"Oncotarget"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2017.05.058","article-title":"Olaparib hydroxamic acid derivatives as dual parp and hdac inhibitors for cancer therapy","volume":"25","author":"Yuan","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0413-z","article-title":"Mthfd1 interaction with brd4 links folate metabolism to transcriptional regulation","volume":"51","author":"Sdelci","year":"2019","journal-title":"Nat Genet"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"B149","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"Brd4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol Cancer"},{"key":"B150","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","article-title":"Super-enhancers and the super-enhancer reader brd4: tumorigenic factors and therapeutic targets","volume":"9","author":"Qian","year":"2023","journal-title":"Cell Death Discovery"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2304534120","article-title":"A deregulated M(6)a writer complex axis driven by brd4 confers an epitranscriptomic vulnerability in combined DNA repair-targeted therapy","volume":"120","author":"Lu","year":"2023","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B152","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","article-title":"Brd4 inhibition is synthetic lethal with parp inhibitors through the induction of homologous recombination deficiency","volume":"33","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal1645","article-title":"Repression of bet activity sensitizes homologous recombination-proficient cancers to parp inhibition","volume":"9","author":"Yang","year":"2017","journal-title":"Sci Trans Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of bet bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.095","article-title":"Bet bromodomain inhibition synergizes with parp inhibitor in epithelial ovarian cancer","volume":"21","author":"Karakashev","year":"2017","journal-title":"Cell Rep"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31898","article-title":"Bet proteins regulate homologous recombination-mediated DNA repair: brcaness and implications for cancer therapy","volume":"144","author":"Mio","year":"2019","journal-title":"Int J Cancer"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01535","article-title":"Discovery of potent and novel dual parp\/brd4 inhibitors for efficient treatment of pancreatic cancer","volume":"64","author":"Wang","year":"2021","journal-title":"J medicinal Chem"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00135","article-title":"Discovery of 4-hydroxyquinazoline derivatives as small molecular bet\/parp1 inhibitors that induce defective homologous recombination and lead to synthetic lethality for triple-negative breast cancer therapy","volume":"65","author":"Zhang","year":"2022","journal-title":"J medicinal Chem"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111718","article-title":"Phosphatidylinositol 3 kinase (Pi3k) inhibitors as new weapon to combat cancer","volume":"183","author":"Elmenier","year":"2019","journal-title":"Eur J Med Chem"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The pi3k pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"B161","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"Akt inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.626","article-title":"Pi3k inhibition results in enhanced her signaling and acquired erk dependency in her2-overexpressing breast cancer","volume":"30","author":"Serra","year":"2011","journal-title":"Oncogene"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"Pi3k inhibition impairs brca1\/2 expression and sensitizes brca-proficient triple-negative breast cancer to parp inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discovery"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2010.06.001","article-title":"Poly(Adp-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets","volume":"20","author":"Chalmers","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12885-015-1090-7","article-title":"Radiosensitization with combined use of olaparib and pi-103 in triple-negative breast cancer","volume":"15","author":"Jang","year":"2015","journal-title":"BMC Cancer"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152584","article-title":"Activation of the pi3k\/mtor pathway following parp inhibition in small cell lung cancer","volume":"11","author":"Cardnell","year":"2016","journal-title":"PLoS One"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a pi3k inhibitor with a parp inhibitor provides an effective therapy for brca1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discovery"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.326","article-title":"Pten deficiency sensitizes endometrioid endometrial cancer to compound parp-pi3k inhibition but not parp inhibition as monotherapy","volume":"37","author":"Bian","year":"2018","journal-title":"Oncogene"},{"key":"B169","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1038\/s41598-021-82990-y","article-title":"Bkm120 sensitizes brca-proficient triple negative breast cancer cells to olaparib through regulating foxm1 and exo1 expression","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw672","article-title":"Phase I dose escalation study of the pi3kinase pathway inhibitor bkm120 and the oral poly (Adp ribose) polymerase (Parp) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer","volume":"28","author":"Matulonis","year":"2017","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3045","article-title":"Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00622","article-title":"Discovery of novel dual poly(Adp-ribose)Polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for cancer therapy","volume":"63","author":"Wang","year":"2020","journal-title":"J medicinal Chem"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113054","article-title":"Discovery of novel parp\/pi3k dual inhibitors with high efficiency against brca-proficient triple negative breast cancer","volume":"213","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113357","article-title":"Discovery of novel and potent parp\/pi3k dual inhibitors for the treatment of cancer","volume":"217","author":"Wu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac908","article-title":"Estrogen regulates divergent transcriptional and epigenetic cell states in breast cancer","volume":"50","author":"Ors","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B176","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","article-title":"Il6\/stat3 signaling hijacks estrogen receptor \u0391 Enhancers to drive breast cancer metastasis","volume":"38","author":"Siersb\u00e6k","year":"2020","journal-title":"Cancer Cell"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.03.078","article-title":"Estrogen: the necessary evil for human health, and ways to tame it","volume":"102","author":"Patel","year":"2018","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2011.05.001","article-title":"Liganded and unliganded activation of estrogen receptor and hormone replacement therapies","volume":"1812","author":"Maggi","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"B179","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/bcr557","article-title":"Regulation of brca1 expression and its relationship to sporadic breast cancer","volume":"5","author":"Mueller","year":"2003","journal-title":"Breast Cancer research: BCR"},{"key":"B180","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng0995-17","article-title":"The developmental pattern of brca1 expression implies a role in differentiation of the breast and other tissues","volume":"11","author":"Marquis","year":"1995","journal-title":"Nat Genet"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1354","article-title":"Brca1 inhibition of estrogen receptor signaling in transfected cells","volume":"284","author":"Fan","year":"1999","journal-title":"Sci (New York NY)"},{"key":"B182","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/sj.onc.1204073","article-title":"Role of direct interaction in brca1 inhibition of estrogen receptor activity","volume":"20","author":"Fan","year":"2001","journal-title":"Oncogene"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208985","article-title":"Modulation of aromatase expression by brca1: A possible link to tissue-specific tumor suppression","volume":"24","author":"Hu","year":"2005","journal-title":"Oncogene"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2021.105853","article-title":"Estrogen enhances the cytotoxicity of parp inhibitors on breast cancer cells through stimulating nitric oxide production","volume":"209","author":"Zhou","year":"2021","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0488","article-title":"Estrogen therapy induces receptor-dependent DNA damage enhanced by parp inhibition in er+ Breast cancer","volume":"29","author":"Traphagen","year":"2023","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"Pd-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003496","article-title":"The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo","volume":"187","author":"Paterson","year":"2011","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal pdl1 in tumour immune evasion","volume":"20","author":"Daassi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"Parp inhibitor upregulates pd-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates pd-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of pd-1\/pd-L1 blockade via combination therapy and pd-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2076","article-title":"Tumor intrinsic pd-L1 promotes DNA repair in distinct cancers and suppresses parp inhibitor-induced synthetic lethality","volume":"82","author":"Kornepati","year":"2022","journal-title":"Cancer Res"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.886170","article-title":"Improving parp inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system","volume":"13","author":"Bound","year":"2022","journal-title":"Front Genet"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"Parp inhibitor efficacy depends on cd8(+) T-cell recruitment via intratumoral sting pathway activation in brca-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discovery"},{"key":"B195","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"Parp inhibition elicits sting-dependent antitumor immunity in brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.1.185","article-title":"A two-step, two-signal model for the primary activation of precursor helper T cells","volume":"96","author":"Bretscher","year":"1999","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123319","article-title":"Parp inhibition enhances tumor cell-intrinsic immunity in ercc1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J Clin Invest"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through sting-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discovery"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"Parpi triggers the sting-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of brcaness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"key":"B200","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-pd-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of parp inhibitor olaparib, and pd-L1 inhibitor durvalumab, in recurrent ovarian cancer: A proof-of-concept phase ii study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2513","article-title":"Phase ii dora study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer","volume":"30","author":"Tan","year":"2024","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35222","article-title":"Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining parp and mek inhibition, with or without anti-pd-L1, for brca wild-type, platinum-sensitive, recurrent ovarian cancer","volume":"130","author":"Mutch","year":"2024","journal-title":"Cancer"},{"key":"B205","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (Ariel2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.657","article-title":"529mo phase ii study of olaparib plus durvalumab with or without bevacizumab (Mediola): final analysis of overall survival in patients with non-germline brca-mutated platinum-sensitive relapsed ovarian cancer","author":"Banerjee","year":"2022","journal-title":"Ann Oncol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202304249","article-title":"Recent progress of supramolecular chemotherapy based on host-guest interactions","volume":"36","author":"Yan","year":"2023","journal-title":"Advanced materials (Deerfield Beach Fla)"},{"key":"B208","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-3-031-27156-4_3","article-title":"Chemotherapy","volume":"185","author":"Hossain","year":"2023","journal-title":"Cancer Treat Res"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.03.006","article-title":"Double-barreled gun: combination of parp inhibitor with conventional chemotherapy","volume":"188","author":"Lu","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B210","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the parp inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (Brightness): A randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.003","article-title":"Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the phase 3 velia\/gog-3005 study","volume":"164","author":"Swisher","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.012","article-title":"Impact of veliparib, paclitaxel dosing regimen, and germline brca status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the velia trial","volume":"164","author":"Aghajanian","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and brca mutation-associated breast cancer (S1416): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-031-27156-4_4","article-title":"Radiation therapies in cancer","volume":"185","author":"Tariq","year":"2023","journal-title":"Cancer Treat Res"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00657-4","article-title":"Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose","volume":"23","author":"Lawhn-Heath","year":"2022","journal-title":"Lancet Oncol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09553009414550021","article-title":"Initial events in the cellular effects of ionizing radiations: clustered damage in DNA","volume":"65","author":"Goodhead","year":"1994","journal-title":"Int J Radiat Biol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00412-017-0658-1","article-title":"Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes","volume":"127","author":"Ranjha","year":"2018","journal-title":"Chromosoma"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020202747","article-title":"Mri-guided radiation therapy: An emerging paradigm in adaptive radiation oncology","volume":"298","author":"Otazo","year":"2021","journal-title":"Radiology"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163888","article-title":"Brca mutations in ovarian and prostate cancer: bench to bedside","volume":"14","author":"Boussios","year":"2022","journal-title":"Cancers"},{"key":"B220","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal transduction targeted Ther"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194874","article-title":"Targeting the DNA damage response and DNA repair pathways to enhance radiosensitivity in colorectal cancer","volume":"14","author":"Deng","year":"2022","journal-title":"Cancers"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i32.7275","article-title":"Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer","volume":"22","author":"Yang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.07.031","article-title":"Replication-dependent radiosensitization of human glioma cells by inhibition of poly(Adp-ribose) polymerase: mechanisms and therapeutic potential","volume":"72","author":"Dungey","year":"2008","journal-title":"Int J Radiat oncology biology Phys"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612978","article-title":"Parp inhibitors and radiotherapy: A new combination for prostate cancer (Systematic review)","volume":"24","author":"Rivero Belench\u00f3n","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0520","article-title":"Parp1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation","volume":"18","author":"Michmerhuizen","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123793","article-title":"Combining parp inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer","volume":"19","author":"C\u00e9saire","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2017.01.007","article-title":"Poly(Adp-ribose) polymerase activity and inhibition in cancer","volume":"63","author":"Dulaney","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.03.003","article-title":"Pre-clinical and clinical evaluation of parp inhibitors as tumour-specific radiosensitisers","volume":"36","author":"Powell","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0278","article-title":"Inhibition of parp-1 by olaparib (Azd2281) increases the radiosensitivity of a lung tumor xenograft","volume":"10","author":"Senra","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B232","article-title":"Function and mechanism of combined parp-1 and brca genes in regulating the radiosensitivity of breast cancer cells","volume":"12","author":"Zhao","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0365","article-title":"Combinatorial efficacy of olaparib with radiation and atr inhibitor requires parp1 protein in homologous recombination-proficient pancreatic cancer","volume":"20","author":"Parsels","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B234","article-title":"A phase I\/ii study of olaparib with entinostat in the treatment of recurrent, platinum-refractory or resistant, homologous recombination repair proficient ovarian, primary peritoneal, and fallopian tube cancers","year":"2019"},{"key":"B235","article-title":"A phase ib combination study of rucaparib (Co-338) and atezolizumab (Mpdl3280a) in participants with advanced gynecologic cancers and triple-negative breast cancer","year":"2017"},{"key":"B236","article-title":"Part 1: avanova1 - a phase I study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (Rp2d) in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer part 2: avanova2 - a two-arm, open-label, phase ii randomized study to evaluate the efficacy of niraparib versus niraparib-bevacizumab combination in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer","year":"2015"},{"key":"B237","article-title":"A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (Ariel3)","year":"2013"},{"key":"B238","article-title":"Phase I\/ii study of cediranib and olaparib in combination for treatment of recurrent papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent triple-negative breast cancer","year":"2010"},{"key":"B239","article-title":"Randomized, double-blind, phase iii trial olaparib vs. Placebo patients with advanced figo stage iiib-iv high grade serious or endometrioid ovarian, fallopian tube, or peritoneal cancer treated standard first-line treatment","year":"2015"},{"key":"B240","article-title":"A phase iii study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer","year":"2015"},{"key":"B241","article-title":"A single-arm phase ii study of olaparib maintenance with pembrolizumab & Bevacizumab in brca non-mutated patients with platinum-sensitive recurrent ovarian cancer (Opeb-01)","year":"2020"},{"key":"B242","article-title":"Phase 1 trial of abt-888 and sch727965 in patients with advanced solid tumors","year":"2011"},{"key":"B243","article-title":"A randomized, molecular driven phase ii trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to hrd status, in patients with advanced (Stage iii B-C-iv) ovarian, primary peritoneal and fallopian tube cancer preceded by a phase I dose escalation study on rucaparib-bevacizumab combination","year":"2018"},{"key":"B244","article-title":"A randomized phase 3, double-blind study of chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for the first-line treatment of brca non-mutated advanced epithelial ovarian cancer (Eoc) (Keylynk-001 \/ engot-ov43 \/ gog-3036)","year":"2018"},{"key":"B245","article-title":"International phase iii randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed ovarian cancer following a response to platinum-based chemotherapy","year":"2017"},{"key":"B246","article-title":"A Phase Iii Randomized, Double-Blinded Trial of Platinum-Based Chemotherapy with or without Atezolizumab Followed by Niraparib Maintenance with or without Atezolizumab in Patients with Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-Free Interval (Tfip) >6 Months","year":"2018"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1441222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:57:30Z","timestamp":1722560250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1441222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":246,"alternative-id":["10.3389\/fonc.2024.1441222"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1441222","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"article-number":"1441222"}}